RANCHO CORDOVA, Calif., Sept. 20, 2012 (GLOBE NEWSWIRE) -- ThermoGenesis Corp. (Nasdaq:KOOL), a leading supplier of enabling technologies for the processing, storage and administration of cell therapies, today reported results for the fourth quarter and all of fiscal 2012.
For the quarter ended June 30, 2012, revenues were $4.5 million versus $5.4 million in the fourth quarter a year ago and $4.9 million in the prior quarter. The decline in year-over-year revenues was attributable to decreased sales of BioArchive® System devices, reflecting the continuing softness in worldwide capital equipment purchase activity. Total disposable sales were higher in the fourth quarter of fiscal 2012 totaling $3.3 million compared to $3.0 million a year ago and $2.9 million in the prior quarter. ThermoGenesis reported a net loss of $738,000, or $0.04 per share, in the fourth quarter of 2012, $430,000 less than the net loss of $1.2 million, or $0.07 per share, in the same period a year ago.
The Company ended the year with $7.9 million in cash compared to $8.5 million at the end of the third quarter and $12.3 million at the end of fiscal 2011. In August 2012, the Company received $2 million in cash related to the sale of assets of the CryoSeal® Fibrin Sealant System (CryoSeal) product line. This payment will be reflected in the Company's balance sheet at September 30, 2012. The Company's backlog at the end of the fourth quarter was $1.5 million.
"Over the past several months, the Company has realized a number of important milestones in its growth strategy, beginning with our recent product purchase and distribution agreement for the AXP® AutoXpress® (AXP) System with Golden Meditech Holdings Limited, which is affiliated with China Cord Blood Corporation—the first and largest umbilical cord blood bank operating in China," said Matthew Plavan, Chief Executive Officer of ThermoGenesis.
Under the five-year agreement, Golden Meditech will have annual minimum purchase commitments and exclusive distribution rights for the AXP System—used for the processing of stem cells from cord blood—in the People's Republic of China (excluding Hong Kong and Taiwan) and in Singapore, Indonesia, India and the Philippines once relevant approvals have been obtained in each respective region where they have not yet occurred.
"We were also pleased to initiate our new integrated distribution programs for our cord blood products with the signing of three new and expanded distribution agreements. These include Concessus for several countries in Western Europe, HVD Biotech Vertriebs for 10 countries in Central and Eastern Europe and 13 Middle Eastern countries, and CEI covering nine countries in Latin America," Plavan added. "These agreements provide a customer-centric approach by incorporating market, service and product support for our cord blood products with a single channel partner by major geography," he noted.
"Finally, we completed the sale of the CryoSeal System to Asahi Kasei Medical Co., Ltd. We are pleased to monetize this non-core asset at a transaction price two and a half times the last three year's average annual revenues generated by this product line. The $2 million cash proceeds from this transaction will be reflected in our September 30, 2012 balance sheet, and will help fund our core, stem cell point of care business initiatives. In addition, this transaction will enable us to reduce operating costs through streamlining of our organization," Plavan continued.
"While our cord blood device product revenues continued to be negatively impacted by the macroeconomic environment this past year, we have accomplished a number of important milestones that we believe will facilitate our efforts to build ThermoGenesis for long term, sustained growth. We have secured new customers and distributor agreements, gained product regulatory approvals in growth geographies, enhanced our competitive position through improved product quality and customer service, successfully demonstrated the safety of our products in clinical evaluations and realized improved operating efficiencies," Plavan said.
"We begin fiscal 2013 well positioned to generate new revenues from our recently signed agreements and further optimize our cost infrastructure. Furthermore, we can increase the trajectory of our revenues by leveraging our technologies into new areas of regenerative medicine by providing tools that enable clinicians to practice cell therapy at the point-of-care or in the laboratory," he added.
For all of fiscal 2012, the Company reported revenues of $19.0 million compared with revenues of $23.4 million in fiscal 2011. Disposable revenues in fiscal 2012 were $13.2 million versus $13.8 million a year ago. The Company reported a net loss of $5.0 million, or $0.30 per share, compared with a net loss of $2.6 million, or $0.17 per share, in the prior year.
Conference Call and Webcast
Management will hold a conference call today at 2 p.m., Pacific (5 p.m., Eastern) to review the fiscal 2012 fourth quarter results.
Conference call details:
To listen to the audio webcast of the call during or after the event, please visit http://www.thermogenesis.com/investors-webcasts-and-calls.aspx
An audio replay of the conference call will be available beginning approximately two hours after completion of the call for the following five business days.
To access the replay:
|Access number (U.S.):||1-877-344-7529|
|Access number (Internationally)||1-412-317-0088|
About ThermoGenesis Corp.
ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These include:
The ThermoGenesis Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=14120
This press release contains forward-looking statements. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors including timing of FDA and foreign regulatory approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal years 2012 and 2013, and introduction of competitive products and other factors beyond our control could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2012 and 2013. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
Web site: http://www.thermogenesis.com
|Condensed Consolidated Balance Sheets|
|Cash and cash equivalents||$7,879,000||$12,309,000|
|Accounts receivable, net||4,558,000||3,963,000|
|Other current assets||338,000||420,000|
|Total current assets||19,065,000||23,040,000|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Other current liabilities||2,259,000||2,273,000|
|Total current liabilities||5,031,000||4,064,000|
|Condensed Consolidated Statements of Operations|
Three Months Ended
|Cost of revenues||3,032,000||3,512,000||12,690,000||14,563,000|
|Selling, general and administrative||1,692,000||2,245,000||7,983,000||8,669,000|
|Research and development||810,000||789,000||3,729,000||3,003,000|
|Total operating expenses||2,502,000||3,034,000||11,712,000||11,672,000|
|Interest and other income, net||315,000||--||393,000||268,000|
|Basic and diluted net loss per common share||($0.04)||($0.07)||($0.30)||($0.17)|
|Shares used in computing per share data||16,408,599||16,346,366||16,389,008||14,816,163|
|Condensed Consolidated Statements of Cash Flows|
|Cash flows from operating activities:|
|Adjustments to reconcile net loss to net cash used in operating activities:|
|Depreciation and amortization||604,000||466,000|
|Stock based compensation expense||791,000||960,000|
|Loss on sale/retirement of equipment||17,000||13,000|
|Loss on impairment of equipment||--||65,000|
|Net change in operating assets and liabilities:|
|Accounts receivable, net||(655,000)||2,132,000|
|Prepaid expenses and other current assets||(38,000)||1,000|
|Accrued payroll and related expenses||223,000||75,000|
|Net cash used in operating activities||(3,885,000)||(2,092,000)|
|Cash flows from investing activities:|
|Proceeds from sale of equipment||--||17,000|
|Net cash (used in)/provided by investing activities:||(545,000)||(249,000)|
|Cash flows from financing activities:|
|Exercise of stock options||--||7,000|
|Issuance of common stock||--||3,914,000|
|Payments on capital lease obligations||--||(2,000)|
|Net cash provided by/(used in) financing activities||--||3,919,000|
|Net increase/(decrease) in cash and cash equivalents||(4,430,000)||1,578,000|
|Cash and cash equivalents at beginning of period||12,309,000||10,731,000|
|Cash and cash equivalents at end of period||$7,879,000||$12,309,000|
Investor Relations +1-916-858-5107, or Email:
Cesca Therapeutics Inc.
Rancho Cordova, California, UNITED STATES
Investor Relations +1-916-858-5107, or Email:
Cesca Therapeutics Inc. logo